|
Dr. Thomas brings to CVBT over two decades of extensive experience at Merck Research Laboratories in scientific research and pharmaceutical development of proteins and small molecular enzyme inhibitors. He is a scientific and managerial expert in biological chemistry molecular biology cell biology and animal pharmacology spanning oncology cardiology endocrinology dermatology and ophthalmology. He has over 80 publications and over 30 issued or pending patents. He has served on The Journal of Biological Chemistry editorial board and has co-organized national/international meetings on protein kinases signal transduction growth factors and angiogenesis.
While at Merck Thomas initiated built and directed the pre-clinical biology programs leading to six development candidates in pro-angiogenesis and anti-angiogenesis which contributed to the development of the hepatitis B recombinant vaccine Recombivax HB.
Dr. Thomas received his Ph.D in Biochemistry from Duke University and his Bachelor of Science degree in Chemistry from the University of Delaware. | 